Roth Capital Downgrades Alexza Pharmaceuticals To Neutral

Roth Capital downgraded Alexza Pharmaceuticals

from Buy to Neutral. The target price for Alexza Pharmaceuticals has been lowered from $10.00 to $5.50. Alexza Pharmaceuticals shares have declined 6.54% over the past 52 weeks, while the S&P 500 index has gained 12.49% in the same period. Alexza Pharmaceuticals' shares gained 2.97% to close at $4.86 yesterday.